Applied research on serum protein fingerprints for prediction of Qi deficiency syndrome and phlegm and blood stasis in patients with non-small cell lung cancer  by Liu, Zhizhen et al.
Online Submissions:http://www.journaltcm.com J Tradit Chin Med 2012 September 15; 32(3): 1-2
info@journaltcm.com ISSN 0255-2922
© 2012 JTCM. All rights reserved.
JTCM |www. journaltcm. com September 15, 2012 |volume 32 | Issue 3 |
CLINICAL OBERVATION
Applied research on serum protein fingerprints for prediction of Qi
deficiency syndrome and phlegm and blood stasis in patients with
non-small cell lung cancer
Zhizhen Liu, Zongyang Yu, Xuenong OuYang, Jian Du, Xiaopeng Lan, Meng Zhao
aa
Zhizhen Liu, Jian Du, Academy of Integrative Medicine of
Fujian University of TCM, Fuzhou, Fujian 350122, China
Zongyang Yu, Xuenong OuYang, Department of Oncolo-
gy, Fuzhou General Hospital, Nanjing Military Area, Fuzhou
350025, China
Xiaopeng Lan, Meng Zhao, PLA Medical Laboratory Center
of Fuzhou General Hospital, Fuzhou 350025, China
Supported by the National Natural Science Foundation of
China (No. 30572293), the "Eleventh Five" TCM Foundation
for Major Clinical Research of PLA (No. 2006051002) and the
Natural Science Foundation of Fujian Province, China (No.
2010J01197)
Correspondence to: Prof. Zongyang Yu, Department of
Oncology, Fuzhou General Hospital, Nanjing Military Area,
Fuzhou 350025, China. yuzy527@yahoo.com.cn
Telephone: +86-591-22859750
Accepted: March 9,2012
Abstract
OBJECTIVE: This study screened serum tumor bio-
markers by surface enhanced laser desorption/ion-
ization time-of-flight mass spectrometry (SEL-
DI-TOF-MS) to establish a subset which could be
used for the prediction of Qi deficiency syndrome
and phlegm and blood stasis in patients with
non-small cell lung cancer; and as diagnostic mod-
el of Chinese medicine.
METHODS: Serum samples from 63 lung cancer pa-
tients with Qi deficiency syndrome and phlegm
and blood stasis, and 28 lung cancer patients with
non-Qi deficiency syndrome and phlegm and
blood stasis were analyzed using SELDI-TOF-MS
with a PBS II-C protein chip reader. Protein profiles
were generated using immobilized metal affinity
capture (IMAC3) protein chips. Differentially-ex-
pressed proteins were screened. Protein peak clus-
tering and classification analyses were performed
using Biomarker Wizard and Biomarker Pattern soft-
ware packages, respectively.
RESULTS: A total of 268 effective protein peaks
were detected in the 1,000-10,000 Da molecular
range for the 15 serum proteins screened (P<0.05).
The decision tree model was M 2284.97, with a sen-
sitivity of 96.2% and a specificity of 66.7%.
CONCLUSION: SELDI-TOF-MS techniques, com-
bined with a decision tree model, can help identify
serum proteomic biomarkers related to Qi deficien-
cy syndrome and phlegm and blood stasis in lung
cancer patients; and the predictive model can be
used to discriminate between Chinese medicine di-
agnostic models of disease.
© 2012 JTCM. All rights reserved.
Key words: Lung neoplasms; Deficiency symptom-
complex; Intermingled phlegm and blood-stasis;
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INTRODUCTION
Lung cancer is the most common malignant tumor,
with more than 1.5 million new cases and more than
1 million deaths per year worldwide. About two thirds
of lung cancer cases are recognized only when in the ad-
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vanced stages.1 We previously found that advanced
lung cancer was caused by a weakness of vital Qi and
phlegm and blood stasis obstructing lung collaterals,
which is a syndrome of deficiency in origin and exces-
sive in superficiality.
Surface enhanced lazar desorption/ionization-time of
flight-mass spectrometry (SELDI-TOF-MS) is a newly
developed proteomics technique which consists of a
protein chip and mass spectrometry.2,3 The technique
has attracted much attention because of its use in the
early detection of cancer, and as an anti-cancer therapy
including drug exploitation. SELDI-TOF-MS can be
used to examine the expression patterns of correlative
proteins in a certain physiologic or pathologic course,
and shows significant value and great potential in bio-
logical research, especially cancer research.4
In the present study, serum samples from lung cancer
patients with Qi deficiency syndrome and phlegm and
blood stasis were analyzed using an immobilized metal
affinity capture (IMAC3) protein chip with SEI-
DI-TOF-MS technology to screen serum for differen-
tially-expressed markers of Qi deficiency syndrome and
phlegm and blood stasis to develop a diagnostic model.
Such a model will aid in the theory of Traditional Chi-
nese Medicine (TCM).
INTRODUCTION
Participant selection
Criteria for enrollment: 1) Patients with non-small cell
lung cancer (NSCLC), confirmed histopathologically;
2) Patients without any treatment; 3) TCM syndrome
differentiation, using the diagnostic criteria for Qi defi-
ciency syndrome and phlegm and blood stasis stipulat-
ed in the TCM Clinical Diagnosis and Treatment Ter-
minology as being: cough, sputum, lassitude, shortness
of breath and a disinclination to talk, lusterless com-
plexion, spontaneous sweating, fear of fresh wind, a
stinging or smarting sensation, a dark and gloomy face,
tongue displaying a white-sticky or petechia coating,
and a weak-thready or rough-thready pulse.
Criteria for exclusion:1) Patients with small cell lung
cancer; 2) Patients with any acute disease; 3) Patients
with liver disease or illness affecting the blood serum
protein content; 4) Patients who have previously under-
gone a surgical operation, chemotherapy, radiotherapy
or biological therapy; and 5) Pregnant or breast-feed-
ing women.
General data: Ninety-one cases of NSCLC met the cri-
teria and were enrolled in the study. Sixty-three cases
were in the Qi deficiency and phlegm and blood stasis
group, which included 44 males and 19 females. The
age of participants ranged between 38-80 years, with
the mean being 58 years. Of the participants, 7 were at
stage I, 14 were at stage II, 14 were at stage III, and 37
where at stage IV. For histopathological classification,
26 cases had squamous carcinoma; 25 had adenoid car-
cinoma; 7 had adenocarcinoma and alveolar carcino-
ma; and 2 had large cell carcinoma.
The control group (non-Qi deficiency and phlegm and
blood stasis) consisted of 28 cases, including 20 males
and 8 females. The age of participants ranged between
35-82 years, with the mean being 55 years. Of the par-
ticipants, 4 were at stage I, 5 where at stage II, 8 where
at stage III, and 11 where at stage IV. For histopatho-
logical classification, 11 cases had squamous carcino-
ma; 12 had adenoid carcinoma; 2 had adenocarcinoma
and alveolar carcinoma; and 1 had large cell carcino-
ma.
There were no significant differences in the age, sex or
the clinical stages between the two groups (P>0.05).
MATERIALS ANDMETHODS
Samples
Peripheral blood was collected from all pre-surgical pa-
tients in the morning after overnight fasting. Samples
were kept at room temperature for 30 min before be-
ing centrifuged at 3,500 rpm for 10 min at 4°C to iso-
late the serum. Serum was stored at -80°C until use.
Preparation of protein chips
Results from preliminary serum protein profiling exper-
iments using three different chip chemistries (a weak
cation-exchanger CM10 chip and an immobilized met-
al affinity capture-copper IMAC3-Cu chip, all from Ci-
phergen, CA, USA) led us to choose the IMAC3-Cu
chip for this study because it yielded the best protein
resolution.
Protein chips were prepared according to the manufac-
turer's instructions. Briefly, each spot on a chip was ac-
tivated using 100μL of copper sulfate (100 mM). Ex-
cessive copper was removed by washing 3 times with
deionized water, incubating with 50 mM sodium ace-
tate (pH 3.0), followed by rinsing 3 more times with
deionized water. Buffering solution (0.01MPBS
with 500 mM NaCl) was applied to each spot and
shaken 3 times for 5 min. The surface around the spots
was wiped dry and excessive buffer was removed. Se-
rum samples were thawed on ice and diluted 1∶40 in
PBS. Diluted sample solution was added to a spot on
the IMAC3-Cu chip and shaken for 90 min. Each spot
was then washed twice with PBS and once with deion-
ized water. When the chip was dry, 0.5μL of energy-ab-
sorbing molecules (EAM) solution (50% sinapinic acid
in 50% acetonitrile and 0.1% trifluoroacetic acid) was
applied to the spots twice as a matrix. Chips were ana-
lyzed with a Protein Biological System II (PBS II) Pro-
teinChip Reader (Ciphergen Biosystems Inc., CA,
USA).
All protein chips used in the study went through a sin-
gle-sample quality control. The coefficients of variance
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(CV) for the peak intensity were between 0.02 and
0.25, suggesting that any experimental errors were
within the acceptable range.
Mass spectrometer analysis
Calibration of the ProteinChip Reader was achieved
with an NP20 chip using All-In-One Peptide Molecu-
lar Mass Standards (Ciphergen Biosystems Inc., CA,
USA). The maximum value for molecular weight col-
lected was set at 100,000 Da, and the optimal range
was set between 1,000-10,000 Da.
Data collection and processing
Mass spectra data obtained from the ProteinChip Read-
er were processed using Ciphergen ProteinChip soft-
ware (Version 3.1.1) for baseline subtraction and com-
mon peak detection. Baseline subtraction was per-
formed on each individual spectrum to eliminate any
baseline signal (caused mainly by chemical noise).
Peaks in all spectra were normalized using peaks at
5915.6 m/z. Noise filtering was achieved using Bio-
marker Wizard software (Version 3.0). Peaks with a sig-
nal/noise ratio of >5 were considered real peaks. After
peak normalization and noise filtering, peaks of similar
molecular weight from the same group were grouped
together into a peak cluster, so that each cluster then
represented a particular protein. Average peak intensi-
ties for a particular cluster were compared between
groups using the student's t test, and the resulting P
values were used to determine whether the protein was
differentially-expressed between two groups. A P value
of <0.05 was considered statistically significant.
Decision tree development
A diagnostic decision tree was generated using Bio-
marker Pattern software (Version 3.1.1). The serum
protein expression spectra for all samples were upload-
ed onto the Biomarker Pattern software to generate de-
cision trees. The sensitivity, specificity, and positive
and negative prediction values for each decision tree
were blindly tested using the serum protein spectra and
clinical diagnosis for the samples in the testing groups.
RESULTS
Fifteen proteins differentially-expressed between Qi de-
ficiency syndrome and phlegm and blood stasis and
non-Qi deficiency syndrome and phlegm and blood
stasis
Comparisons of serum protein expression profiles be-
tween Qi deficiency syndrome and phlegm and blood
stasis and non-Qi deficiency syndrome and phlegm
and blood stasis in patients revealed 15 proteins were
differentially-expressed at a statistically significant level
(P<0.05). Among them, 6 proteins, with molecular
weights of 1490.14, 1518.06, 2209.18, 4745.96,
5205.92 and 6840.99 Da were downregulated Qi defi-
ciency syndrome and phlegm and blood stasis (QD-
PBS) compared with non-Qi deficiency syndrome and
phlegm and blood stasis (non-QDPBS) (Table 1).
Nine proteins with molecular weights of 1260.60,
1528.54, 2075.74, 2083.15, 2284.98, 2510.17,
2857.69, 2894.21 and 6970.05 Da were upregulated
(Table 2).
Table 1 Proteins upregulated in patients with Qi deficiency
syndrome and phlegm and blood stasis
Molecular
weight
1260.60
1528.54
2075.74
2083.15
2284.98
2510.17
2857.69
2894.21
6970.05
Protein peak
QDPBS
patients
1.2±1.4
1.4±1.2
1.7±2.4
2.5±2.3
2.5±2.4
2.2±1.8
5.0±5.8
1.7±1.5
4.1±5.3
Non-QDPBS
patients
0.3±0.7
0.6±0.6
0.2±0.5
1.1±0.6
0.8±0.6
1.1±0.6
1.3±1.3
0.8±0.3
1.3±1.3
P value
0.049
0.042
0.010
0.012
0.021
0.026
0.039
0.042
0.012
Notes: All protein peak values are shown as mean±standard
deviation. Sixty-three QDPBS, and 28 non-QDPBS patients.
Table 2 Proteins downregulated in patients withQi deficien-
cy syndrome and phlegm and blood stasis
Molecular
weight
1490.14
1518.06
2209.18
4745.96
5205.92
6840.99
Protein peak
QDPBS
patients
0.9±1.3
2.0±2.9
0.5±0.9
0.5±0.7
0.8±0.9
2.0±2.0
Non-QDPBS
patients
2.2±1.3
5.1±5.0
1.1±0.6
1.0±0.9
1.8±1.8
5.1±4.3
P value
0.012
0.015
0.027
0.039
0.019
0.022
Notes: All protein peak values are shown as mean±standard
deviation. Sixty-three QDPBS, and 28 non-QDPBS patients.
Decision tree development to predict Qi deficiency
syndrome and phlegm and blood stasis with NSCLC
To evaluate the clinical significance of differentially-ex-
pressed proteins identified in this study, we developed
a decision tree using Biomarker Pattern software based
on the protein expression profiles from 63 samples
from patients with Qi deficiency syndrome and
phlegm and blood stasis and samples from 28 patients
with non-Qi deficiency syndrome and phlegm and
blood stasis (Figure 3).
The decision tree had one judgment node and two ter-
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minal nodes. When blindly applied to the test group
containing the remaining 63 samples from patients
with Qi deficiency syndrome and phlegm and blood
stasis and the 28 samples from patients with non-Qi de-
ficiency syndrome and phlegm and blood stasis con-
trols, the forecasting accuracy was 83.52% (76/91), the
sensitivity was 96.2%, and the specificity was 66.7% .
The detection ratios of QDPBS and non-QPBS pa-
tients were 79.4% (50/63) and 92.86% (26/28), re-
spectively. The area under the ROC curve of the deci-
sion tree was 0.870.
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Figure 3 Decision tree for detection of Qi deficiency syndrome and phlegm and blood stasis
Figure 1 Mass spectrum (upper panel) and photograph of gel (lower panel) of fraction collected from an IMAC column that con-
tained upregulated protein peaks at 2857.69, 6970.05m/z (indicated by arrow)
Al and A2 are QDPBS patients; B1 and B2 are non-QDPBS patients.
Figure 2 Mass spectrum (upper panel) and photograph of gel (lower panel) of fraction collected from an IMAC column that con-
tained the downregulated protein peaks at 1518.06, 6840.99m/z (indicated by arrow)
Al and A2 are QDPBS patients; B1 and B2 are non-QDPBS patients.
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DISCUSSION
Syndrome differentiation in TCM is a method used to
recognize and analyze syndromes of disease. Its unique
concept of "dialectic wholism theory" provides for the
possibility of using proteomic techniques. Applying
proteomics technology, analyzing protein compositions
of different syndromes of a same disease and different
diseases of a same syndrome, screening expression pro-
files of protein, and using bioinformatics and statistical
analyses, can build a specific protein data mine of a
disease syndrome type. To explore the relationship be-
tween syndromes and the expression profile of pro-
teins, we set up a forecasting model,5 which revealed
the scientific connotation of traditional Chinese medi-
cal syndrome and provides a reliable basis and method
for diagnosis.
SELDI-TOF-MS integrates a protein chip with mass
spectrometry technology, which can directly analyze a
sample, such as blood, urine, saliva and other clinical
samples, without purification and with convenient op-
eration and sample consumption, and also obtain more
single and repeatable maps. In recent years, advanced
developments have been made in SELDI-TOF-MS
technology, making the detection of cancer faster and
more effective. In 2008, Zhao Jian et al6 used the weak
cation exchanger protein chip (WCX2) to analyze se-
rum from 12 lung cancer patients with Qi and yin defi-
ciency and 12 lung cancer patients with Qi stagnation
and blood stasis. They identified 6 different markers
and created a decision tree (diagnostic model) with a
sensitivity of 66.67% and a specificity of 100%.These
results suggest that SELDI-TOF-MS technology may
establish new TCM syndrome differentiation models
for lung cancer.
The present study analyzed serum from 63 lung cancer
patients with Qi deficiency syndrome and phlegm and
blood stasis and compared it with 28 lung cancer pa-
tients with non-Qi deficiency syndrome and phlegm
and blood stasis using an IMAC3 chip, and successful-
ly discriminated the changing processes of Qi deficien-
cy syndrome and phlegm and blood stasis by using a
panel of 15 biomarkers. Nine of these markers were up-
regulated and 6 were downregulated in patients with
Qi deficiency syndrome and phlegm and blood stasis.
Two candidate protein peaks, with the m/z value of
2284.97, were selected to establish a predictive model
using biomarker pattern software (BPS) with a sensitivi-
ty of 96.2% (25/33) and a specificity of 66.7% (51/
62). These 15 differentially-expressed protein peaks
were different from previous reports because of the dif-
ferences in the ages of participants, histopathological
classification and TNM stage, and the specific ioniza-
tion and chip surface conditions used (WCX2 and
IMAC3 ProteinChip). It will be necessary to further ex-
tend the sample size, or use a new mathematical model
(such as an artificial neural network), to improve on
this classification diagnosis model by giving it a higher
accuracy.
SELDI-TOF-MS is an automatic proteomic technique
with high throughput and sensitivity and has recently
been applied to research on traditional Chinese medi-
cine syndrome types. However, some aspects of the
SELDI-TOF-MS technology are still under develop-
ment, such as isolation, identification and building a
protein database. It is believed that with the develop-
ments in life sciences, proteomic techniques and bioin-
formatics, understanding the mechanisms of the inter-
nal relationship between disease and syndrome will im-
prove to such a point at which they can provide a new
basis for TCM therapy.
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